Sentence examples for trial of acquisition from inspiring English sources

We generated these scores by dividing the number of correct responses at Short Delay Free Recall (or Long Delay Free Recall) by the number of correct responses at the last trial of acquisition of CVLT, and multiplying the answer by 100.

To analyze acquisition, we ran Training Group PITT, PVT) × CS (CS+, CS−) × Time (First Trial of Acquisition, Last Trial of Acquisition) mixed models with SR, shock US expectancy, and self-report fear as dependent variables.

All three measures had significantly higher values for CS+ than CS− at the last trial of acquisition.

There was a significant increase in responding to the CS+ from the first to last trial of acquisition for self-report fear and shock US expectancy but not SR.

There was also a significant decrease in responding to the CS− from the first trial of acquisition to the first trial of extinction for SR and shock US expectancy but not self-report fear.

In order to demonstrate that the differences in the reacquisition trials are not caused by a better acquisition of the task in the first trials we calculated a covariance analysis with the last trial of the acquisition period as a covariate.

Mean reaction times were calculated for each of the conditions, over the initial 25 trials, indicative of acquisition, and across the final 50 trials, indicative of asymptotic learning.

Repeated measures ANOVA revealed no significant difference in the mean RT's between the 2 conditions (DLPFC rTMS vs. sham) over the first 25 trials, indicative of acquisition rate, or the final 50 trials, indicative of asymptotic performance.

A separate analysis considered whether the first reference memory error made in each testing trial was more likely to be to the single, never-baited arm or one of the adjacent, never-baited arms, over each of the eight, four-trial blocks of acquisition.

Because results from cell culture experiments suggested that mutations accumulate in viral genomes before a population collapse, we examined the HIV-1 populations derived from the Phase IIa trial for acquisition of excess A to G and G to A mutations in the viral genome consistent with the mechanism of action of the drug [15].

The discussants all agreed that closer collaboration should be centered in the following areas: 1) biomarker-adaptive clinical trial; 2) standardization of acquisition and analysis of biospecimens; 3) regulatory framework to test combinations of investigational drugs; and 4) center of excellence of clinical oncology trials in China.